CRS-207: Clinical Trials

9 trials of CRS-207, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 3 terminated. 9 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 29Completed 6, Terminated 3
Phase 11Terminated 1

Follow CRS-207: new trials by email Literature Review of CRS-207 trials Research Report on CRS-207

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
Tadalafil, Pembrolizumab, Ipilimumab - Pancreatic Cancer
Phase 2CompletedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins172022-08-222026-04-28
Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
Epacadostat, Pembrolizumab, CRS-207 - Metastatic Pancreatic Adenocarcinoma
Phase 2CompletedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins412018-01-312024-10-08
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
Cyclophosphamide, Nivolumab, Ipilimumab - Pancreatic Cancer
Phase 2CompletedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins612017-12-142024-08-07
Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers
CRS-207, Pembrolizumab - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Phase 2TerminatedAduro Biotech, Inc.52017-08-142019-04-04
Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
CRS-207, Pembrolizumab - Malignant Pleural Mesothelioma
Phase 2TerminatedAduro Biotech, Inc.102017-05-312019-04-04
Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer
CRS-207, Epacadostat, Pembrolizumab - Platinum-resistant Ovarian Cancer, Platinum-resistant Fallopian Cancer
Phase 1 / Phase 2TerminatedAduro Biotech, Inc.352016-03-082019-04-04
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
CRS-207, nivolumab, GVAX - Previously Treated Metastatic Adenocarcinoma of the Pancreas
Phase 2CompletedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins932015-01-022021-04-06
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
GVAX Pancreas Vaccine, CRS-207, Chemotherapy - 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
Phase 2CompletedAduro Biotech, Inc.3032014-02-052018-06-04
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
GVAX Pancreas, CRS-207, Cyclophosphamide - Metastatic Pancreatic Cancer
Phase 2CompletedAduro Biotech, Inc.932011-09-212018-05-08

Conditions studied

Pancreatic Neoplasms (4)  ·  Neoplasms (3)  ·  Adenocarcinoma (2)  ·  Carcinoma (2)  ·  Adenocarcinoma Of Esophagus (1)  ·  Digestive System Diseases (1)  ·  Esophageal Neoplasms (1)  ·  Gastrointestinal Diseases (1)  ·  Mesothelioma, Malignant (1)  ·  Ovarian Neoplasms (1)  ·  Stomach Diseases (1)  ·  Stomach Neoplasms (1)

Sponsors

Aduro Biotech, Inc. (5)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4)

Countries

United States (9)  ·  Canada (2)

Top investigators

Dung Le, MD (2)  ·  Dung Le, M.D. (1)  ·  Dung T Le, MD (1)  ·  Katherine Bever, MD (1)

Results publications

PMID 29997287, PMID 31126960

NIH funding

P01CA247886 (3)